Quality of life (e.g. absence from school, lost time at work, mobility) as assessed by any validated questionnaire either generic or SCD specific) ‐ not measured · people with sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Tinzaparin vs placebo

Hospitalisation (number and duration) ‐ not measured · people with sickle cell disease

1 finding from 1 review

Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 253 participants
Very low

Tinzaparin vs placebo

Participant satisfaction with the medication assessed by any appropriate and validated questionnaire (either generic or SCD specific) ‐ not measured · people with sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Tinzaparin vs placebo

Adverse events associated with the use of anticoagulants (e.g. bleeding) · people with sickle cell disease

Tinzaparin showed no clear difference in adverse events associated with the use of anticoagulants (e.g.… compared with placebo (low certainty).

1 finding from 1 review

Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only
RR 4.96 [0.24, 102.31]
1 study · 253 participants
Low